Classification of segmental vitiligo on the trunk N. van Geel, S. Bosma, B. Boone and R. Speeckaert
|
|
- Ruth Phelps
- 5 years ago
- Views:
Transcription
1 PLAIN LANGUAGE SUMMARIES Classification of segmental vitiligo on the trunk N. van Geel, S. Bosma, B. Boone and R. Speeckaert This summary relates to DOI: /bjd British Journal of Dermatology, 170, , February 2014 BJD British Journal of Dermatology In vitiligo, areas of skin lose their normal pigment (colour) and become white, due to an absence of pigment cells called melanocytes. It is an autoimmune condition, in which the body s immune system (which normally fights off disease) rejects some of its own, healthy cells melanocytes in the case of vitiligo. In segmental vitiligo the patches only occur on one part of the body, such as the leg, face or trunk. In this study, researchers from Belgium examined images of 106 segmental vitiligo lesions (patches) occurring on the trunks of 104 patients, to see where they occur ( distribution ) and to identify any patterns. Segmental vitiligo was more frequently found on the ventral side of the trunk (lower part, near the abdomen 859%) compared to the lateral part (the sides 528%) and the back (368%). Based on common patterns, lesions were categorised into six subtypes: type 1, 2 and 3 involved the upper part of the trunk, type 4 and 5 the middle part and type 6 the lower part. 679% of all segmental vitiligo lesions could fit into these subtypes. The most frequent type of lesion was subtype 3 (226%), which showed a V- shaped pattern on the upper trunk, followed by subtype 5 (179%), a band-like pattern on the lateral side, and subtype 6 (132%), a rectangular shape on the lower abdomen. Categorising segmental vitiligo on the trunk may help doctors to predict where the disease is most likely to spread to on a patient and allow for early treatment of the area of risk. It may also help doctors to diagnose whether a patient has segmental vitiligo or nonsegmental vitiligo (vitiligo which appears not just on one body part) in its initial stage, in addition to helping differentiate it from other types of pigment disorders. The impact of skin damage due to cutaneous lupus on quality of life S.M. Verma, J. Okawa, K.J. Propert and V.P. Werth This summary relates to DOI: /bjd British Journal of Dermatology, 170, , February 2014 Lupus is a serious, long-term autoimmune disease (meaning the body s immune system, which is meant to defend against disease, attacks the body s own, healthy cells). Systemic lupus erythematosus (SLE) is the most common type of lupus and can potentially affect the whole body, including skin, joints and organs. Cutaneous lupus erythematosus (CLE) is a form that affects the skin alone. There are several types of CLE with different symptoms. It is already known that CLE can cause poorer quality of life in patients. This US-based study of 141 patients looked more specifically at the impact on quality of life of disease damage (mainly scarring and discolouration of the skin) caused by the disease. The study also examined how disease damage affects people of different ethnicities, namely Caucasian, African American and Asian. The researchers found that, contrary to their expectations, the severity of disease damage was not linked to how greatly quality of life was impaired, and that it is the disease activity (how severe the symptoms are) that has a negative impact on quality of life rather than disease damage. This is of interest as it differs to other skin diseases that cause pigment changes, such as vitiligo, where quality of life is greatly impacted 2014 British Association of Dermatologists British Journal of Dermatology (2014) 170, pp1 5 e1
2 e2 Plain Language Summaries by skin discolouration. The researchers also found differences between the racial backgrounds relating to how disease activity impacts on disease damage and when disease damage first manifests itself. Antidrug antibodies in psoriasis: a systematic review L. Hsu, B.T. Snodgrass and A.W. Armstrong This summary relates to DOI: /bjd British Journal of Dermatology, 170, , February 2014 Psoriasis is a common skin disease in which the body produces too much of a protein called tumour necrosis factor alpha (TNF-alpha) which in turn causes inflammation. Adalimumab, etanercept, infliximab and ustekinumab are four powerful biological drugs (or biologics so named because they mimic normal human molecules) used to treat psoriasis due to their ability to reduce the activity of TNF-alpha. However, the body s immune system, which normally fights off infection, can produce antidrug antibodies (or ADAs) that see biologics as harmful invaders and try to deactivate them. The US-based researchers looked at 25 studies, involving 7969 patients, to explore three issues: how prevalent ADAs are in patients receiving biologics, whether they influence how effective the drug is, and whether taking the psoriasis treatment drug methotrexate in unison with a biologic can help prevent ADAs forming. 950 (12%) of the patients tested positive for ADAs. In some of the studies involving adalimumab and infliximab this was associated with reduced levels and efficacy of the drug. ADAs caused by etanercept were not found to affect the patients treatment responses, while those caused by ustekinumab may cause reduced treatment response. However, the results are unclear. Methotrexate was associated with less ADA formation in patients receiving infliximab or adalimumab but further studies are needed. The authors found great variability in the rate of ADA detection in psoriasis patients and highlight that a number of other factors may influence ADA formation, including genetics and disease type. They conclude that ADAs acting against certain biologic agents may influence treatment efficacy. Screening for tinea unguium by dermatophyte test strip Y. Tsunemi, K. Takehara, Y. Miura, G. Nakagami, H. Sanada and M. Kawashima This summary relates to DOI: /bjd British Journal of Dermatology, 170, , February 2014 Tinea unguium, also known as onychomycosis or, more commonly, as fungal nail infection, causes infected nails to turn white or yellowish and become thickened and crumbly. It is very common, affecting up to 13% of the general population and up to 25% of elderly people. Traditionally, testing for tinea unguium has involved taking samples of the nail and examining them under a microscope ( microscopy ), using a variety of different methods. However, it can take several weeks for the results of these tests to be available and results can vary depending of the skills of the person analyzing the samples. This study looks at a new testing method, using a dermatophyte test strip. This method involves adding small nail samples to a solution in a test tube and then using a test strip that displays a brown line if the sample is positive for the fungus. The process takes about 20 min. The researchers, from Japan, compared results from 165 nail samples, tested using both the test strip and microscopy. They found that the new method had a high level of accuracy British Journal of Dermatology (2014) 170, pp British Association of Dermatologists
3 Plain Language Summaries e3 in detecting the infection and gave no false negative results. The authors recommend that samples that are positive from a dermatophyte test strip should then be confirmed using microscopy. Those that test negative do not require this extra step, reducing the overall number of microscopy tests required. Investigation of cutaneous photoadaptation to narrowband ultraviolet B S. Darne, L.C. Stewart, P.M. Farr and P.J. Hampton This summary relates to DOI: /bjd British Journal of Dermatology, 170, , February 2014 Phototherapy is a treatment involving ultraviolet light (either UVA or UVB) which is used for a range of diseases, including a common skin disorder called psoriasis. In UVB treatment, patients can receive the full UVB light spectrum, called broadband UVB (BBUVB), or just a small part, called narrowband UVB (NBUVB). This is done in a hospital at regular intervals over many weeks or months. Photoadaptation is the natural process by which the skin becomes increasingly accustomed to UV light, as a result of repeated exposure to it, and therefore is able to withstand an increased UV dose. For example, tanning and skin thickening are responses to UV exposure and both allow the skin to tolerate higher levels of UV. For this reason UV doses are often increased during a patient s course of phototherapy. This study, from the UK, is one of the first to measure photoadaptation to NBUVB, as opposed to the more widely studied BBUVB. The researchers measured the minimal erythemal dose (MED) of 50 patients, before and towards the end of a 20 week course of treatment. MED is the minimum amount of UVB that it takes to cause skin redness 24 h later. As the skin becomes more accustomed to UV the MED increases (i.e. it takes a greater dose of UVB to turn the skin red). The researchers found that patients tolerate, on average, 27 times the dose of UV radiation at the end of NBUVB phototherapy than at the start. This is considerably less than reported for BBUVB. This study is the first step towards calculating accurate phototherapy dose increases for NBUVB. Efficacy and safety of systemic treatments for moderate-tosevere psoriasis: meta-analysis of randomised controlled trials J. Schmitt, S. Rosumeck, G. Thomaschewski, B. Sporbeck, E. Haufe and A. Nast This summary relates to DOI: /bjd British Journal of Dermatology, 170, , February 2014 This study is a review of randomised controlled trials (RCTs) investigating treatments for psoriasis, including biological drugs (or biologics - so named because they mimic normal human molecules). RCTs are studies in which a number of similar patients are randomly allocated to two or more test groups, one of which will be a con British Association of Dermatologists British Journal of Dermatology (2014) 170, pp1 5
4 e4 Plain Language Summaries trol group (receiving either no treatment or a placebo) while the other groups will each receive one of the specific treatments being tested. The different groups of patients are then monitored in the exact same way allowing for direct comparison between different treatments and / or between the treatment and control groups. This study examines the results from 48 different RCTs, comprising patients involved in biologics RCTs and 1888 patients involved in RCTs for conventional treatments. The researchers, from Germany, looked at efficacy and safety of 8 different systemic drugs (affecting the whole body rather than applied to the skin s surface) and measured effectiveness as a 75% or more reduction in a patient s PASI score, which assesses the severity and extent of an individual s psoriasis. As indicators of a drug s safety in each treatment group they looked at numbers of adverse events (unwanted side effects), proportions of patients with at least one adverse event, and withdrawals from the study. The researchers found that in placebo-controlled trials biologics are more effective than all conventional treatments. Two types of biologics, called adalimumab and infliximab, were deemed more effective than a non-biologic drug called methotrexate, and a biologic called ustekinumab was found to have better results than one called etanercept. The researchers conclude, however, that reporting of adverse events is too varied to allow for definitive, direct comparisons between the drugs, and state that international agreement on how adverse events should be monitored in psoriasis trials is urgently required. Immune responses to hair dyes containing toluene-2,5- diamine J.D. Schmidt, J.D. Johansen, M.M. Nielsen, E. Zimersson, C. Svedman, M. Bruze, K. Engkilde, S.S. Poulsen, C. Geisler and C.M. Bonefeld This summary relates to DOI: /bjd British Journal of Dermatology, 170, , February 2014 Permanent hair dyes are known to cause skin allergies in some people, and the allergen (allergy-causing substance) of most concern in dyes in called p-phenylenediamine or PPD. This study, by researchers from Denmark and Sweden, looked at the role of another dye called toluene-2,5-diamine (PTD) used in such products, as this is commonly used in dyes on the Scandinavian market. Two commercially available hair dyes containing PTD and were tested on skin and as a control compared with the response to 025%, 1% and 4% PTD, and 4% PPD. The study looked at immune responses to the dyes, meaning how the body s immune system, which normally fights off infection or unwanted cells, reacts to the chemical. These responses include skin inflammation, and how certain cells infiltrate the body s lymph nodes (part of the body s immune system). Treatment with 1% PTD was found to cause the same level of skin inflammation, measured in terms of swelling, as 4% PPD, implying that lower levels of PTD are needed to cause inflammation. They also found that the PTD-containing dyes trigger immune responses that both cause and fight inflammation, which may be why consumers can use these potent mixtures of allergens without getting a severe reaction. The authors conclude that the scale of the immune responses depends on the PTD concentration and possibly on the number of other possible allergens in the dye, as well as on the exposure regime. British Journal of Dermatology (2014) 170, pp British Association of Dermatologists
5 Plain Language Summaries e5 Reduction of unwanted submental fat with ATX-101, an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study B. Rzany, T. Griffiths, P. Walker, S. Lippert, J. McDiarmid and B. Havlickova This summary relates to DOI: /bjd British Journal of Dermatology, 170, , February 2014 This study examined a potential therapy for reducing submental fat fat deposits underneath the chin, known more colloquially as a double chin. The treatment involves injecting submental fat with ATX-101, a laboratory-created or synthetically derived formulation of a naturally occuring bile called deoxycholic acid. The injection irreversibly disrupts fat cell membranes and causes destruction of fat cells called adipocytolysis. The cellular debris resulting from the destruction of the fat cells is then removed by special cells called macrophages which are triggered by an inflammatory response to the injection of ATX-101. The study, by researchers in the US, UK and Germany, included 363 men and women with moderate to severe submental fat. The primary goals of the trial were to demonstrate at least a one point improvement in submental fat on the 5-point Clinician-Reported Submental Fat Rating Scale and for patients to show satisfaction with their face and chin appearance on the 7-point Subject Self- Rating Scale (SSRS). The trial used two different dosages of ATX-101 (1 mg cm 2 and 2 mg cm 2 ) as well as a placebo. With the higher dosage of ATX-101, 653% of patients had a reduction in submental fat of at least one point on the Clinician-Reported Submental Fat Rating Scale compared with 230% with the placebo, and 661% of patients were happy with their face and chin appearance, vs. 287% for the placebo. In addition, calliper measurements showed a significant reduction in submental fat. Following treatment, patients also reported a reduction in the psychological impact they felt due to the appearance of their face and chin. The authors conclude that subcutaneous injections with ATX-101 yield a clinically meaningful and statistically significant reduction in unwanted submental fat, decrease the psychological impact on patients, and are well tolerated, and that this treatment is a novel, non-surgical approach to treatment of submental fat British Association of Dermatologists British Journal of Dermatology (2014) 170, pp1 5
Scottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce
More information5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris
87 5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris Supported by the EDF/EADV/IPC Pathirana, D.; Ormerod, A. D.; Saiag, P.; Smith, C.; Spuls, P. I.; Nast, A.; Barker, J.; Bos, J.
More informationOriginal Policy Date
MP 2.01.58 Light Therapy for Vitiligo Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical Policy
More informationPediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.
Original Issue Date (Created): January 1, 2010 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Preauthorization Requirements for Ustekinumab (STELARA ) Note:
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationGLOSSARY of research terms
GLOSSARY of research terms SETTING PRIORITIES FOR VITILIGO RESEARCH - WORKSHOP Thursday 25 th March 2010 Types of studies Case Series: A study reporting on a consecutive collection of patients, treated
More informationOriginal Policy Date
MP 2.01.07 Psoralens with Ultraviolet A (PUVA) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed by consensus/12:2013 Return to Medical Policy
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationPredicting the Response to Phototherapy for Psoriasis Patients
A*STAR-NHG-NTU Skin Research Grant Joint Workshop 17 October 2015 Predicting the Response to Phototherapy for Psoriasis Patients Is it possible? Dr Eugene Tan Consultant Dermatologist National Skin Centre
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationSnapshot Dx Quiz: September 2018 Detailed Answers
Snapshot Dx Quiz: September 2018 Detailed Answers Cynthia X. Wang, BA 1 Milan J. Anadkat, MD 1,2 1 Washington University School of Medicine, St. Louis, Missouri 2 Division of Dermatology, St. Louis, Missouri
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Dimethyl fumarate for treating moderate to severe Draft scope (pre-referral) Draft remit/appraisal objective To appraise
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationWhy have I been selected for treatment with adalimumab?
ADALIMUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about adalimumab (Humira TM ). It tells you what it is, how it works, how it is used to treat skin
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationFollow this and additional works at: Part of the Skin and Connective Tissue Diseases Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is the Addition of a Topical Agent to
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368
Apremilast for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368 NICE 2015. All rights reserved. Contents 1 Guidance...
More informationMelanoma: The Basics. What is a melanocyte?
Melanoma: The Basics What is a melanocyte? A melanocyte is a normal cell, found in the skin, which produces melanin. Melanin is a black or dark brown pigment that is seen in the skin, hair, and parts of
More informationustekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More informationVITILIGO. Made by: Basma Noor, Maryam Mahjoub, Irin Chankao and Sara Samadi.
VITILIGO Made by: Basma Noor, Maryam Mahjoub, Irin Chankao and Sara Samadi. What is Vitiligo? Vitiligo is a chronic skin disease (a long-lasting condition that can be controlled but not cured) characterized
More informationImmune System.notebook March 07, Maintaining Dynamic Equilibrium. Immune system 1st, 2nd and 3rd line of defense Immune disorders
Unit 3 Maintaining Dynamic Equilibrium Immune system 1st, 2nd and 3rd line of defense Immune disorders Oct 11 3:27 PM p.382 386 Immune system A complex system involving several organs and tissues (e.g.
More informationA systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C
A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C Authors' objectives To compare the effectiveness of currently available treatments
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationRisankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis
NIHR Innovation Observatory Evidence Briefing: November 2017 Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis NIHRIO (HSRIC) ID: 9708 NICE ID: 9191 LAY SUMMARY Plaque
More informationA class IIa medical device intended for mild-to-moderate fungal nail infection PRODUCT MONOGRAPH
A class IIa medical device intended for mild-to-moderate fungal nail infection PRODUCT MONOGRAPH AWB-2052628721 Date of Preparation March 2017 Introduction to Bayer Bayer is a Life Science company with
More informationPsoriatic Arthritis- Secondary Care
Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442
Ixekizumab for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 NICE 2017. All rights reserved. Subject to Notice of rights
More informationWR SKIN. DERMATOLOGY
WR SKIN. DERMATOLOGY 1 Societies 11 History 13 Dictionaries. Encyclopaedias. Bibliographies Use for general works only. Classify with specific aspect 15 Classification. Nomenclature 16 Tables. Statistics
More informationCorrespondence should be addressed to Amir Kalafi;
ISRN Dermatology, Article ID 472546, 6 pages http://dx.doi.org/10.1155/2014/472546 Clinical Study Evaluation of the Efficacy of Topical Tetracycline in Enhancing the Effect of Narrow Band UVB against Vitiligo:
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationUstekinumab for the treatment of moderate to severe psoriasis
DOI: 10.3310/hta13suppl3/10 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Ustekinumab for the treatment of moderate to severe psoriasis E Gospodarevskaya, J Picot, K Cooper, E Loveman* and A Takeda
More informationCOMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio
COMMON SKIN CONDITIONS IN PRIMARY CARE Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio DISCLOSURE The Speaker and members of the planning committee do not have a conflict of interest
More informationDRAFT FOR PUBLIC CONSULTATION. Clinical Commissioning Policy Proposition: Infliximab for the treatment of hidradenitis suppurativa
Clinical Commissioning Policy Proposition: Infliximab for the treatment of hidradenitis suppurativa Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages and over,
More informationJosephine Mauskopf Miny Samuel Doreen McBride Usha G. Mallya Steven R. Feldman
PharmacoEconomics (2014) 32:395 409 DOI 10.1007/s40273-014-0130-5 SYSTEMATIC REVIEW Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review
More informationWhat to do when patch testing is negative?
What to do when patch testing is negative? Christen M. Mowad MD Clinical Professor of Dermatology Geisinger Medical Center Danville, PA 17821 cmowad@geisinger.edu I have no disclosures. What to do when
More informationCorporate Medical Policy
Corporate Medical Policy Light Therapy for Dermatologic Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: light_therapy_for_dermatologic_conditions 5/2012 11/2017 11/2018
More information3 rd Appraisal Committee meeting, 28 February 2017 Committee D
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple Technology Appraisal 3 rd Appraisal Committee
More informationTHE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS Mădălina FRÎNCU 1 Abstract: Biological
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION IXEKIZUMAB (Taltz Eli Lilly Canada Inc.) Indication: Moderate to Severe Plaque Psoriasis Recommendation: The CADTH Canadian Drug Expert Committee
More informationTHE EFFECTS OF REPEATED SUB-ERYTHEMAL EXPOSURES OF UVR ON HUMAN IMMUNITY
THE EFFECTS OF REPEATED SUB-ERYTHEMAL EXPOSURES OF UVR ON HUMAN IMMUNITY Joanna Narbutt Department of Dermatology Medical University of Lodz, Lodz, Poland Photoimmunosuppression ULTRAVIOLET RADIATION DNA
More informationLUPUS. The Skin and Hair LUPUSUK 2015
5 LUPUS The Skin and Hair LUPUSUK 2015 LUPUS The Skin and Hair Skin problems are very common in lupus and many different types of issues can occur. This factsheet will discuss some of the more frequent
More informationA Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients
Volume 1, Issue 3 Research Article A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients Darukarnphut P, Rattanakaemakorn P *, Rajatanavin N Division
More informationEFFECTIVENESS AND SAFETY OF NARROW BAND ULTRAVIOLET B THERAPY IN CHRONIC PLAQUE PSORIASIS
ORIGINAL ARTICLE EFFECTIVENESS AND SAFETY OF NARROW BAND ULTRAVIOLET B THERAPY IN CHRONIC PLAQUE PSORIASIS 1 4 Mohammad Majid Paracha, Irfanullah, Zafar Ali, Said Amin ABSTRACT Objectives: To determine
More informationSkin Care in Renal Transplant Patients
Skin Care in Renal Transplant Patients Introduction Skin Care in Renal Transplant Patients Skin care is very important for everyone, but particularly for renal patients who have received transplants. Because
More informationMELANOMA. Some people are more likely to get a m Melanoma than others:
MELANOMA This leaflet has been written to help you understand more about Melanoma. It tells you what is it, what causes it, what can be done about it, how it can be prevented, and where you can find out
More informationKrunal Amin 7/17/2010 Josh Cannon Topics in Biology
SUMMER VENTURES UNC CHARLOTTE 2010 1 Malignant Melanoma Krunal Amin 7/17/2010 Josh Cannon Topics in Biology 2 Abstract Malignant melanoma is a cancer of melanocytes. It is caused by environmental (mainly
More informationhttps://www.printo.it/pediatric-rheumatology/gb/intro Scleroderma Version of 2016 1. WHAT IS SCLERODERMA 1.1 What is it? The name scleroderma is derived from Greek and can be translated as "hard skin".
More informationBJD. Summary. British Journal of Dermatology THERAPEUTICS
THERAPEUTICS BJD British Journal of Dermatology Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry
More informationKEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.
KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated
More informationInvited Re vie W. Antinuclear antibody-keratinocyte interactions in photosensitive cutaneous lupus erythematosus
Histol Histopathol (1 999) 14: 627-633 http://www.ehu.es/histol-histopathol Histology and Histopathology Invited Re vie W Antinuclear antibody-keratinocyte interactions in photosensitive cutaneous lupus
More informationWhat Are the Different Forms?
SCARRING/CICATRICIAL ALOPECIA Scarring alopecia also known as cicatricial alopecia, refers to a collection of hair loss disorders that may be diagnosed in up to 3% of hair loss patients. It occurs worldwide
More informationTechnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 NICE 2017. All rights
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationDermatology GP Referral Guidelines
Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:
More informationBilaga 1.till rapport. Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies
Bilaga 1.till rapport Ljusbehandling och systemisk behandling av psoriasis, rapport nr 278 (2018) Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies Description of included
More informationThis questionnaire was used both during the face-to-face interviews with the
Additional file 1: Primary research questionnaire This questionnaire was used both during the face-to-face interviews with the dermatologists and during the expert panel 1. During the last month, how many
More informationTHE CANCER/MITOSIS CONNECTION
THE CANCER/MITOSIS CONNECTION All cells have a controlled rate of division that is appropriate for their role in the body. Rates of Division ex. The cells of the skin reproduces perfectly so that it does
More informationMaking decisions about available treatments
TREATMENTS Making decisions about available treatments The aim of this ebooklet is to help you think through the choices that are available to you. It includes: the factors which might influence your decisions.
More informationPUVA: Shall we still use it for psoriasis in 2019?
PUVA: Shall we still use it for psoriasis in 2019? Ben Stoff MD, MA Associate Professor Emory Department of Dermatology Phototherapy: F003 March 1, 2019 DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationMELANOMA. 4 Fitzroy Square, London W1T 5HQ Tel: Fax: Registered Charity No.
MELANOMA This leaflet had been written to help you understand more about melanoma. It tells you what it is, what causes it, what can be done about it, how it can be prevented, and where you can find out
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationBackground Head Quarter Promoter Holding Pattern Turnover
PhotoMedex, Inc INTRODUCTION Background PhotoMedex is a global skin health medical technology company, providing integrated disease management and aesthetic solutions through complementary laser and light-based
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationHorizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationClinical Trial Report Synopsis
Clinical Trial Report Synopsis A phase 2a, proof of concept trial, testing twice daily application of LEO 124249 ointment 30 mg/g in the treatment of mild to moderate inverse psoriasis Design of trial:
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationPsoriasis. What is Psoriasis? What causes psoriasis? Medical Topics Psoriasis
1 Psoriasis What is Psoriasis? Psoriasis is a long standing inflammatory non-contagious skin disease which waxes and wanes with triggering factors. There is a genetic predisposition in psoriasis. Internationally,
More informationINFLAMMATORY BOWEL DISEASE AND SKIN HEALTH KARA N. SHAH, MD, PHD KENWOOD DERMATOLOGY MARCH 4, 2018
INFLAMMATORY BOWEL DISEASE AND SKIN HEALTH KARA N. SHAH, MD, PHD KENWOOD DERMATOLOGY MARCH 4, 2018 DISCLOSURES I HAVE NO RELEVANT FINANCIAL DISCLOSURES INTRODUCTION Structure and function of the skin IBD
More informationPsoriasis: Causes, Symptoms, And Treatment
Psoriasis: Causes, Symptoms, And Treatment We all know that a healthy immune system is good. But, do you know that an overactive immune system can cause certain conditions like Psoriasis? Read on to find
More informationAppendix H: Study characteristics: Fungal infections, Mycoses. The Epidemiology of Skin Conditions in the Aged: A Systematic Review.
Appendix H: Study characteristics: Fungal infections, Mycoses Article title: Journal: The Epidemiology of Skin Conditions in the Aged: A Systematic Review. Journal of Tissue Viability 1 Nr. Source (Author
More informationHow The Skin Tans. How The Skin Tans
How The Skin Tans How The Skin Tans Our natural skin colour is determined by skin pigment melanin and the presence and amount of melanin in an individual is determined by hereditary factors. When our skin
More informationIxekizumab for treating moderate to severe plaque psoriasis [ID904]
Thank you for agreeing to make a submission on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationComparison of the efficacy of PUVA versus BBUVB in the treatment of psoriasis vulgaris
IJMAMR 5 (2017) 1-6 ISSN 2053-1834 Comparison of the efficacy of PUVA versus BBUVB in the treatment of psoriasis vulgaris Tran Hau Khang* and Le Huu Doanh National Hospital of Dermatology and Venereology,
More informationDefinition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he
LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. Rowan Diagnostic Clinic Salisbury, N.C. May 11, 2013 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationCOMMUNICABLE DISEASES
Name MOD: Date COMMUNICABLE DISEASES Journal Question: Complete in journal section of notebook 1. A is a condition that interferes with the proper functioning of the body or mind, and can be broken down
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationAn otherwise healthy 12-year-old
1105 Photo Rounds.finalREV 10/19/05 2:05 PM Page 947 A young girl with scaly skin plaques The patient had numerous thick red plaques on her back and the extensor surfaces of elbows, knees, and forearms
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More informationSecukinumab (plaque psoriasis)
IQWiG Reports Commission No. A17-08 Secukinumab (plaque psoriasis) Benefit assessment according to 35a Social Code Book V 1 (new scientific findings) Extract 1 Translation of Sections 2.1 to 2.6 of the
More informationBreakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING
More informationFor personal use only
Company Announcement Observations from Clinuvel s vitiligo and EPP programs being presented at the American Academy of Dermatology SCENESSE (afamelanotide 16mg implant) data and clinical reports to be
More informationIt is estimated that about 26,000 new cases of
Focus on CME at Dalhousie University Set On Soothing Psoriasis A. H. Murray, MD, FRCP(C) Presented at the 76th Annual Dalhousie Refresher Course It is estimated that about 26,000 new cases of psoriasis
More informationMelanoma What It Is and How To Reduce Your Risk
www.melanomafocus.com Melanoma What It Is and How To Reduce Your Risk 1 Melanoma What It Is And How To Reduce Your Risk What is melanoma? It is a potentially serious form of cancer, usually starting in
More informationEfficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis
Efficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis T. Shehzad ( Departments of Dermatology Naval Hospital PNS Shifa, Karachi. ) N. R. Dar ( Departments
More informationDESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S
Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity
More informationInvolving patients in research experiences from the eczema priority setting partnership
Involving patients in research experiences from the eczema priority setting partnership Professor Kim Thomas, Deputy Director Centre of Evidence Based Dermatology Aims What is a Priority Setting Partnership
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationIxekizumab (plaque psoriasis)
IQWiG Reports Commission No. A17-07 Ixekizumab (plaque psoriasis) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ixekizumab
More information